The association between insomnia and insomnia treatment side effects on health status, work productivity, and healthcare resource use

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  DiBonaventura, Marco ^a   Richard, Lance ^b   Kumar, Maya ^a   Forsythe, Anna ^c   Flores, Natalia M ^a   Moline, Margaret ^c  

^a KANTAR HEALTH   (United States)

^b EISAI CO LTD   (Japan)

^c EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HEALTH CARE PLANNING; HEALTH STATUS; HUMAN; INSOMNIA; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PHYSICAL INACTIVITY; PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; SHORT FORM 36; SMOKING; SOCIAL STATUS; UNEMPLOYMENT; UNITED STATES; ADVERSE DRUG REACTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; MEDICATION COMPLIANCE; MIDDLE AGED; QUESTIONNAIRE; SLEEP INITIATION AND MAINTENANCE DISORDERS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EFFICIENCY; FEMALE; HEALTH RESOURCES; HEALTH STATUS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUALITY OF LIFE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 84947253995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137117     Document Type: Article

References (32)

1. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999; Suppl 2: :S347-53. PMID: 10394606
2. Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C. Epidemiology of insomnia: Prevalence, selfhelp treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006; 7:123-30. PMID: 16459140
3. Bolge S, Doan J, Kannan H, Baran R. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res. 2009; 18:415-22. doi: 10.1007/s11136-009-9462-6 PMID: 19288223
4. Ishak WW, Bagot K, Thomas S, Magakian N, Bedwani D, Larson D, et al. Quality of life in patients suffering from insomnia. Innov Clin Neurosci. 2012; 9:13-26. PMID: 23198273
5. Daley M, Morin CM, LeBlanc M, Gregoire J-P, Savard J. The Economic Burden of Insomnia: Direct and Indirect Costs for Individuals with Insomnia Syndrome, Insomnia Symptoms, and Good Sleepers. Sleep. 2009; 32:55-64. PMID: 19189779
6. Asnis G, Chakraburtty A, DuBoff E, Krystal A, Londborg P, Rosenberg R, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999; 60:668-76. PMID: 10549683
7. Krystal A, Walsh J, Laska E, Caron J, Amato D, Wessel T, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003; 26:793-9. PMID: 14655910
8. Uchiyama M, Hamamura M, Kuwano T, Nishiyama H, Nagata H, Uchimura N. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med. 2011; 12:119-26. doi: 10.1016/j.sleep.2010.08.010 PMID: 21256803
9. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005; 48:301-10. PMID: 15695169
10. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005; 331:1169. PMID: 16284208
11. Najib J. Eszopiclone, a Nonbenzodiazepine Sedative-Hypnotic Agent for the Treatment of Transient and Chronic Insomnia. Clin Ther. 2006; 28:491-516. PMID: 16750462
12. Tagaya H. Pharmacotherapy of insomnia in clinical medicine. Folia Pharmacol Jpn. 2007; 129:42-6.
13. Rosenberg RP. Sleep Maintenance Insomnia: Strengths and Weaknesses of Current Pharmacologic Therapies. Ann Clin Psychiatry. 2006; 18:49-56. PMID: 16517453
14. Ramakrishnan K. Treatment Options for Insomnia. South Afr Fam Pract. 2007; 49:34-41.
15. Lightspeed Online Research, Inc. Global Panels. 2011. Available: http://www.lightspeedresearch.com/online-market-research-survey-panels. Accessed 26 October 2011.
16. U.S. Census Bureau. Current population survey (CPS). 2012. Available: http://www.census.gov/cps/data/. Accessed 30 January 2014.
17. DiBonaventura M, Wagner J, Yuan Y, L'Italien G, Langley P, Ray Kim W. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ. 2010; 13:709-18. doi: 10.3111/13696998.2010.535576 PMID: 21091098
18. Finkelstein EA, Allaire BT, DiBonaventura M daCosta, Burgess SM. Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes. J Occup Environ Med. 2011; 53:1025-9. doi: 10.1097/JOM.0b013e318229aae4 PMID: 21866052
19. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008; 10:348-54.
20. Charlson M, Pompei P, Ales K, Ronald MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40:373-83. PMID: 3558716
21. Ware J, Kosinski M, Turner-Bowker D, Gandek B. How to Score Version 2 of the SF-12 Health Survey (With a supplement documenting version). Quality Metric Inc. Lincoln, RI; 2002.
22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002; 21:271-92. PMID: 11939242
23. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004; 13:873-84. PMID: 15362179
24. Walters S, Brazier J. What is the relationship between the minimally important differene and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003; 1:4. PMID: 12737635
25. Reilly M, Zbrozek A, Dukes E. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4:353-65. PMID: 10146874
26. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. SAS Conference Proceedings. Long Beach, CA; 2011. p. 214-26.
27. Butner KL, Hargens TA, Kaleth AS, Miller LE, Zedalis D, Herbert WG. Association of Obstructive Sleep Apnea Severity with Exercise Capacity and Health-related Quality of Life. N Am J Med Sci. 2013 Jun; 5 (6):362-6. doi: 10.4103/1947-2714.114168 PMID: 23923110
28. Moline M, DiBonaventura MD, Shah D, Ben-Joseph R. Impact of middle-of-the-night awakenings on health status, activity impairment, and costs. Nat Sci Sleep. 2014; 6:101-11. doi: 10.2147/NSS. S66696 PMID: 25093001
29. Villa KF, Black J, Chervin RD, Flores NM, Witt EA. Resource use, productivity loss, and economic burden of narcolepsy: Results from the National Health and Wellness Survey. Poster presented at the Academy of Managed Care Pharmacy 2014 Nexus Meeting. October 7-10, 2014. Boston, MA.
30. Laugsand LE, Strand LB, Vatten LJ, Janszky I, Bjørngaard JH. Insomnia symptoms and risk for unintentional fatal injuries-the HUNT Study. Sleep. 2014; 37:1777-86. doi: 10.5665/sleep.4170 PMID: 25364073
31. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014; 37(2):343-9. doi: 10.5665/sleep.3410 PMID: 24497662
32. Victorri-Vigneau C, Gérardin M, Rousselet M, Guerlais M, Grall-Bronnec M, Jolliet P. An update on zolpidem abuse and dependence. J Addict Dis. 2014; 33(1):15-23. doi: 10.1080/10550887.2014.882725 PMID: 24467433